CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
Liraglutide Pen Injector +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04199728
NCT04199728Phase 2Completed
CompareCT.gov

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

Milton S. Hershey Medical Center·interventional·Posted Dec 16, 2019·Updated Nov 6, 2024

In Brief

A Phase 2 clinical trial evaluating Liraglutide Pen Injector and Placebo for Opiate Substitution Treatment and Opioid-Related Disorders. Completed, enrolled 27 participants across 1 site.

Detailed Summary

This research is being done to find out if liraglutide (brand name is Saxenda®) can safely and effectively reduce craving for opioids in patients with opioid use disorder, a primary factor contributing to early relapse.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpiate Substitution Treatment, Opioid-Related Disorders
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 16, 2019
Enrollment StartOct 18, 2021
Primary CompletionSep 13, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.5 years ago

Interventions

Liraglutide Pen Injectordrug

Liraglutide will be provided using an injection pen provided by the manufacturer

Placebodrug

Placebo injection pen